PROGRAM
Opening lectures and conference dinner on Tuesday 26th will be at the Bellinzona Institutes of Science building (BIOS+).
Presentations, coffee breaks and lunches on Wednesday 27th, Thursday 28th and Friday 29th will be at Auditorium Banca Stato.
September 26
September 27
September 28
September 29
September 26
Bellinzona Institute of Science building (BIOS+)
Informal, standing dinner (Italian Pizza and drinks)
Offered by the IRB-Rockefeller University partnership for infectious diseases research
| 14:00 – 16:00 | Registration and welcome remarks |
| Opening lectures | 16:00 – 16:40 |
Keynote speaker:
Davide Robbiani Institute for Research in Biomedicine (IRB), Bellinzona, Switzerland Antibodies against virus and chemokines after COVID-19 |
| 16:40 – 17:20 |
Keynote speaker:
Christian Klein Roche, Zürich, Switzerland PD-1 cis-targeting of IL2v with the PD1-IL2v immunocytokine to overcome the limitations of aldesleukin and biased IL-2Rbg agonists |
Offered by the IRB-Rockefeller University partnership for infectious diseases research
September 27
Auditorium Banca Stato
| Session 1: Immunotherapy of viral diseases | |
| 9:00 – 9:30 | Registration |
| 9:30 – 10:00 |
Santiago Gonzalez Institute for Research in Biomedicine (IRB), Bellinzona, Switzerland The administration of anti-influenza HA antibodies induces an immunosuppression mechanism that impairs the presentation of antigens by lymph node dentritic cells |
| 10:00 – 10:20 |
Radislav Sedlacek Institute of Molecular Genetics (IMG), Czech Academy of Sciences, Czech Republic The Czech Centre for Phenogenomics: the gate to comprehensive description of gene functions. |
| 10:20 – 10:40 | Break |
| 10:40 – 11:20 |
Keynote speaker:
Felix Rey Institute Pasteur, Paris, France The icosahedral “herringbone” organization of the flavivirus particle confers Mab C10 its extraordinary neutralization breadth |
| 11:20 – 11:40 | Selected abstract for one oral presentation-Eliska Kotounová Biology Centre CAS, Branisovska, Ceske Budejovice, Czech Republic Novel antibodies against Tick-Borne Encephalitis virus Non-Structural Protein 1. |
| 11:40 – 12:20 |
Keynote speaker:
Eva Harris University of California (UC), Berkeley, USA Antibody correlates of protection and risk for Dengue virus symptomatic infection and severe disease. |
| 12:20 – 14:00 | Lunch |
| Session 2: Antibody-drug development (Part 1) | |
| 14:00 – 14:40 |
Keynote speaker:
Adriano Aguzzi University of Zürich, Zürich, Switzerland Elucidating the basis of prion infectivity and toxicity with the T.spiezzo and T.gonfio arrayed CRISPR libraries. |
| 14:40 – 15:00 | Selected abstract for one oral presentation-Tania Vanzolini University of Urbino Carlo Bo, Urbino, Italy Dia-T51, a humanized monoclonal antibody for the treatment of Candida auris and other fungal infections. |
| 15:00 – 15:40 |
Keynote speaker:
Dario Neri Philogen & ETH Zürich, Siena & Zürich, Italy & Switzerland Antibody-toxin conjugates |
| 15:40 – 16:00 | Selected abstract for one oral presentation-Giulio Pierleoni Fondazione Toscana Life Sciences & University of Siena, Siena, Italy A novel approach to anticipate the evolution of SARS-CoV-2 escape mutations to therapeutic monoclonal antibodies. |
| 16:00 – 16:20 | Break |
| 16:20 – 17:00 |
Keynote speaker:
Baolin Zhang Food and Drug Administration (FDA), Silver Spring, USA Advancing immunotherapy: key insights into potency assay development for antibody-based therapies |
September 28
Auditorium Banca Stato
| Session 3: Host-directed immunotherapies | |
| 9:30 – 10:00 | Nuria Izquierdo-Useros IrsiCaixa, Badalona, Spain When antigen-presenting cells go viral: targeting viral dissemination with anti-Siglec-1 mAbs |
| 10:00 – 10:20 | Selected abstract for one oral presentation-Matteo Stravalaci IRCCS Humanitas Research Hospital, Italy Use of Mannose Binding Lectin as therapeutic agent in COVID-19. |
| 10:20 – 10:40 | Break |
| 10:40 – 11:10 | Sarah Gerlo UGent, Gent, Belgium Targeting cytokine activity: towards applications in infectious disease. |
| 11:10 – 11:40 | Stylianos Bournazos The Rockefeller University, NY, USA Protective and pathogenic activities of the IgG Fc domain |
| 11:40 – 12:00 | Selected abstract for one oral presentation-Annalisa Ciabattini University of Siena, Italy Profiling the immune response to SARS-CoV-2 vaccination in different cohorts of fragile subjects. |
| 12:00 – 14:00 | Lunch |
| Session 4: Antibody-drug development (Part 2) | |
| 14:00 – 14:40 | Keynote speaker: Giuseppe Pantaleo CHUV, University of Lausanne, Lausanne, Switzerland Novel potent neutralization antibodies active against all circulating SARS-CoV-2 VOCs. |
| 14:40 – 15:00 | Selected abstract for one oral presentation-Giampiero Batani Fondazione Toscana Life Sciences, Siena, Italy Development of a new functional assay for assessing the anti-bacterial activity of human monoclonal antibodies against Shigella. |
| 15:00 – 15:30 | Janice Reichert The antibody society, USA Antibody therapeutics for infectious disease: commercial development trends |
| 15:30 – 16:00 | Arnaud Avril IRBA, Brétigny-sur-Orge, France Development of antibodies for biodefense. The example of an antibody neutralizing several species of Orthopoxvirus |
| 16:40 – 17:20 | Keynote speaker: Federica Sallusto Institute of Research in Biomedicine (IRB) & ETH Zürich, Bellinzona & Zurich, Switzerland Antibodies against conserved coronavirus epitopes. |
| Bellinzona Institutes of Science building (BIOS+) | |
| 18:00 – 20:00 | Poster session |
Standing Dinner
Offered by IBSA Institut Biochimique SA
September 29
Auditorium Banca Stato
| Session 5: Immunotherapy of non-viral diseases | |
| 9:30 – 10:00 |
András N. Spaan University Medical Center (UMC), Utrecht, Netherlands Towards immunotherapy for staphylococcal infections: human genetics as a compass |
| 10:00 – 10:20 | Selected abstract for one oral presentation-Barnabas G. Williams University of Oxford, UK A fusion CyRPA-Ripr protein in combination with RH5: a novel tripartite blood-stage malaria vaccine candidate. |
| 10:20 – 10:40 | Break |
| 10:40 – 11:10 |
Fabio Bagnoli GSK, Siena, Italy Immunotherapy against bacterial diseases |
| Closing lecture | |
| 11:10 – 11:50 |
Keynote speaker:
Davide Corti Humabs BioMed, a subsidiary of VIR Biotechnology, Bellinzona, Switzerland Antibodies against infectious diseases |
| 11:50 – 12:20 | Conclusion and remarks |